Navigation Links
Reportlinker Adds Biomarker Partnering Terms and Agreements
Date:4/12/2011

NEW YORK, April 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarker Partnering Terms and Agreements

http://www.reportlinker.com/p0471283/Biomarker-Partnering-Terms-and-Agreements.html

Summary

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

* Trends in biomarker partnering deals

* Biomarker partnering agreement structure

* Biomarker partnering contract documents

* Top biomarker deals by value

* Most active biomarker dealmakers

Description

The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1000 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2005, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2005. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2005, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in biomarker partnering and dealmaking since 2000.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Key benefits

Biomarker Partnering Terms and Agreements provides the reader with the following Key benefits:

* In-depth understanding of biomarker deal trends since 2000

* Access to headline, upfront, milestone and royalty data

* Analysis of the structure of biomarker agreements with numerous real life case studies

* Comprehensive access to over 1000 actual biomarker contracts entered into by the world's biopharma companies

* Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies

* Insight into the terms included in a biomarker agreement, together with real world clause examples

* Understand the key deal terms companies have agreed in previous deals

* Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

* Trends in biomarker dealmaking in the biopharma industry since 2005

* Analysis of biomarker deal structure

* Access to headline, upfront, milestone and royalty data

* Case studies of real-life biomarker deals

* Access to over 1000 biomarker contract documents

* The leading biomarker deals by value since 2005

* Most active biomarker dealmakers since 2005

* The leading biomarker partnering resources

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

* Company A-Z

* Headline value

* Stage of development at signing

* Deal component type

* Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1000 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

* What are the precise biomarker rights granted or optioned?

* What is actually granted by the agreement to the partner company?

* What exclusivity is granted?

* What is the payment structure for the deal?

* How are sales and payments audited?

* What is the deal term?

* How are the key terms of the agreement defined?

* How are IPRs handled and owned?

* Who is responsible for commercialization?

* Who is responsible for development, supply, and manufacture?

* How is confidentiality and publication managed?

* How are disputes to be resolved?

* Under what conditions can the deal be terminated?

* What happens when there is a change of ownership?

* What sublicensing and subcontracting provisions have been agreed?

* Which boilerplate clauses does the company insist upon?

* Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

* Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in biomarker dealmaking

• 2.1. Introduction

• 2.2. Biomarker partnering over the years

• 2.3. Bigpharma biomarker dealmaking activity

• 2.4. Bigpharma not active in biomarkers

• 2.5. Biomarker partnering by deal type

• 2.6. Biomarker partnering by disease type

• 2.7 Average deal terms for biomarkers

• 2.7.1 Biomarker headline values

• 2.7.2 Biomarker upfront payments

• 2.7.3 Biomarker milestone payments

• 2.7.4 Biomarker royalty rate

Chapter 3 – Leading biomarker deals

• 3.1. Introduction

• 3.2. Top biomarker deals by value

• 3.3. Top biomarker deals involving bigpharma

Chapter 4 – Bigpharma biomarker deals

• 4.1. Introduction

• 4.2. How to use bigpharma biomarker partnering deals

• 4.3. Bigpharma biomarker partnering company profiles

• Abbott

• Actavis

• Alcon Labs

• Allergan

• Amgen

• Apotex

• Astellas

• AstraZeneca

• Baxter International

• Bayer

• Biogen Idec

• Boehringer Ingelheim

• Bristol-Myers Squibb

• Celgene

• Cephalon

• Chugai

• CSL

• Daiichi Sankyo

• Dainippon Sumitomo

• Eisai

• Eli Lilly

• Forest Laboratories

• Genzyme

• Gilead Sciences

• GlaxoSmithKline

• Hospira

• Johnson & Johnson

• Kyowa Hakko Kirin

• Lundbeck

• Meda

• Menarini

• Merck & Co

• Merck KGaA

• Mitsubishi Tanabe

• Mylan

• Novartis

• Novo Nordisk

• Nycomed Pharma

• Otsuka

• Pfizer

• Ratiopharm

• Roche

• Sanofi-Aventis

• Servier

• Shionogi

• Shire

• Takeda

• Teva

• UCB

• Watson

Chapter 5 – Biomarker dealmaking directory

• 5.1. Introduction

• 5.2. Company A-Z

• 5.3. By stage of development

• Discovery

• Pre-clinical

• Phase I

• Phase II

• Phase III

• Registration

• Marketed

• 5.4. By deal type

• Asset and product purchase

• Collaborative R&D

• Co-development

• Co-marketing

• Co-promotion

• Development

• Distribution

• Evaluation

• Joint venture

• Licensing

• Manufacturing

• Marketing

• Option

• Promotion

• Research

• Supply

• 5.5. By therapy area

• Hospital care

• Cardiovascular

• Central nervous system

• Dental

• Dermatology

• Gastrointestinal

• Genetic disorders

• Genitourinary

• Hematology

• Genetic disorders

• Immunology

• Infection

• Inflammatory

• Metabolic

• Musculoskeletal

• Oncology

• Ophthalmics

• Respiratory

• Sensory organ

• Animal health

Chapter 6 – Biomarker partnering resource center

• 6.1. Online biomarker partnering

• 6.2. Biomarker partnering events

• 6.3. Further reading on biomarker dealmaking

Appendices

• Appendix 1 – Deal type definitions

• Appendix 2 – Example biomarker partnering agreement

• About Wildwood Ventures

Figures in report

• Figure 1: Biomarker partnering since 2005

• Figure 2: Bigpharma – top 50 – biomarker deals 2005 to 2010

• Figure 3: Inactive bigpharma in biomarkers 2005-2010

• Figure 4: Biomarker partnering by deal type since 2005

• Figure 5: Biomarker partnering by disease type since 2005

• Figure 6: Biomarker partnering by oncology target since 2005

• Figure 7: Biomarker deals with a headline value

• Figure 8: Biomarker deal headline value distribution, US$million

• Figure 9: Biomarker deal headline value distribution, US$million

• Figure 10: Biomarker deals with upfront payment values

• Figure 11: Biomarker deal upfront payment distribution, US$million

• Figure 12: Biomarker deals with milestone payments

• Figure 13: Biomarker deal milestone payment distribution, US$million

• Figure 14: Biomarker deals with royalty rates, %

• Figure 15: Biomarker deal royalty rate distribution, %

• Figure 16: Top biomarker deals by value since 2005

• Figure 17: Top biomarker deals signed by bigpharma value since 2005

• Figure 18: Online partnering resources

• Figure 19: Forthcoming partnering events

• Figure 20: Deal type definitions

• Figure 21: Biomarker partnering agreement between GlaxoSmithKline and Response Genetics, May 2010

To order this report:

: Biomarker Partnering Terms and Agreements

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
2. Reportlinker Adds Industrial Biotechnology China News 1103
3. Reportlinker Adds DNA Sequencing - Technologies, Markets and Companies
4. Reportlinker Adds Cytogenetics - Technologies, Markets and Companies
5. Reportlinker Adds Animal Biotechnology - Technologies, Markets and Companies
6. Reportlinker Adds Antiviral Therapeutics - Technologies, Markets and Companies
7. Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
8. Reportlinker Adds Molecular Diagnostics Markets
9. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
10. Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment
11. Reportlinker Adds Quantum Dots: Technologies and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
Breaking Biology Technology:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):